Genzyme’s Framingham Plant Clears FDA; Restoring Full Supply Could Take All Year
Executive Summary
The subsidiary of Sanofi long has pegged opening of additional plant as critical to restoring full production of Fabrazyme, which has been rationed to Fabry disease patients since a manufacturing interruption in 2009.
You may also be interested in...
China Orphan Drug Reimbursement: Swift Action Needed – Former Genzyme GM
Only 1% of 5,781 rare diseases in China have effective treatments. Facing reimbursement and infrastructure challenges, the market needs rapid action from government and industry, says Shirley Zhao, former Genzyme China general manager.
China Orphan Drug Reimbursement: Swift Action Needed – Former Genzyme GM
Only 1% of 5,781 rare diseases in China have effective treatments. Facing reimbursement and infrastructure challenges, the market needs rapid action from government and industry, says Shirley Zhao, former Genzyme China general manager.
Pfizer/Protalix’s Elelyso Offers Gaucher Patients A Vegetarian Option
Gaucher disease enzyme-replacement therapy Elelyso is the first FDA-approved plant-cell based recombinant therapeutic protein, a biosimilar option that may eliminate the production-related problems Genzyme’s Cerezyme and Shire’s Vpriv face with animal cell-based processes. Pfizer is launching Elelyso at a 25% discount to Cerezyme and promising to maintain a two-year supply.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: